Table 1 Clinical Characteristics of the Study Group
| Â | Â | Â | Â | Â | P | ||
|---|---|---|---|---|---|---|---|
| Â | All | A -CMR | B +CMR-S | C +CMR+S | B vs A | C vs A | C vs B |
N | 559 | 350 | 166 | 43 | Â | Â | Â |
Age, yrs | 70.4 ± 10.7 | 71.6 ± 10.7 | 68.3 ± 10.6 | 68.5 ± 10.6 | 0.0007 | 0.0704 | 0.8714 |
Men, n (%) | 436 (78) | 275 (79) | 123 (74) | 38 (88) | 0.1203 | ||
NYHA class | 3.31 ± 0.5 | 3.35 ± 0.5 | 3.20 ± 0.40 | 3.37 ± 0.49 | 0.0004 | 0.8115 | 0.0287 |
   III | 385 (69) | 225 (64) | 133 (80) | 27 (63) |  |  |  |
CRT-D, n (%) | 87 (16) | 52 (15) | 27 (16) | 8 (19) | 0.7799 | ||
Co-morbidity, No. (%) | Â | Â | Â | Â | Â | Â | Â |
   Diabetes mellitus | 90 (16) | 55 (16) | 25 (15) | 10 (24) | 0.4248 | ||
   Hypertension | 149 (27) | 93 (17) | 44 (27) | 12 (28) | 0.9575 | ||
   Coronary artery bypass | 112 (20) | 65 (19) | 30 (18) | 17 (40) | 0.0048 | ||
Medication, No. (%) | Â | Â | Â | Â | Â | Â | Â |
   Loop diuretics | 495 (89) | 314 (90) | 144 (87) | 37 (86) | 0.2619 | ||
   ACE-I or ARB | 498 (89) | 306 (87) | 151 (91) | 41 (95) | 0.3392 | ||
   Beta-blockers | 300 (54) | 177 (51) | 97 (58) | 26 (60) | 0.2641 | ||
   Spironolactone | 224 (40) | 138 (39) | 65 (39) | 17 (40) | 0.9142 | ||
ECG variables | Â | Â | Â | Â | Â | Â | Â |
Chronic atrial fibrillation, No. (%) | 119 (21) | 86 (25) | 29 (17) | 4 (9) | 0.0249 | ||
   QRS duration, ms | 154.3 ± 28.5 | 158.5 ± 29.5 | 148.6 ± 25.4 | 144.5 ± 26.0 | 0.0003 | 0.0022 | 0.3860 |
Echocardiography | Â | Â | Â | Â | Â | Â | Â |
   LVEDV, mL | 259.0 ± 109.0 | 252.5 ± 107.2 | 268.3 ± 115.1 | 267.5 ± 97.2 | 0.1938 | 0.4489 | 0.9703 |
   LVESV, mL | 200.9 ± 94.5 | 196.5 ± 92.2 | 207.2 ± 101.2 | 206.0 ± 83.8 | 0.3109 | 0.5820 | 0.9466 |
   LVEF, % | 23.5 ± 10.1 | 23.2 ± 10.4 | 24.1 ± 9.9 | 23.7 ± 8.6 | 0.4346 | 0.7832 | 0.8465 |